NASDAQ:ZYME Zymeworks Q3 2026 Earnings Date & Estimates $25.79 +0.53 (+2.10%) Closing price 04:00 PM EasternExtended Trading$25.79 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zymeworks is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Zymeworks in Q3 2026Zymeworks is expected to post earnings of $2.29 per share on revenue of $227.39 million. In the same quarter a year earlier Zymeworks reported -$0.26 per share on revenue of $27.61 million. Zymeworks last reported on August 7, 2026, posting -$0.62 per share and missing the -$0.5620 consensus estimate. Zymeworks has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS$2.29Expected Revenue$227.39 millionPrior-Year EPS-$0.26Prior-Year Revenue$27.61 millionExpected Revenue Growth+723.4%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.62 (Missed by -$0.0580)Last Quarter Revenue$3.23 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Zymeworks Q3 2026 Earnings FAQ When does Zymeworks report Q3 2026 earnings? Zymeworks (NASDAQ:ZYME) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. What time is Zymeworks' Q3 2026 earnings call? Zymeworks' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Zymeworks? Analysts expect Zymeworks to post earnings of $2.29 per share for Q3 2026. How much revenue is Zymeworks expected to report? The consensus revenue estimate for Zymeworks is $227.39 million for Q3 2026. Zymeworks Earnings HeadlinesZymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO HireOctober 9 at 6:00 AM | finance.yahoo.comZymeworks (NASDAQ:ZYME) Stock Picked Up by Analysts at TD CowenOctober 1, 2026 | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 9 at 1:00 AM | Weiss Ratings (Ad)Copertura su Zymeworks ripristinata con Buy da TD Cowen sull’acquisizioneSeptember 29, 2026 | it.investing.comZymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 GuidanceSeptember 28, 2026 | finance.yahoo.comZymeworks Inc. Updates Earnings Guidance for the Year 2026September 28, 2026 | marketscreener.comMSee More Zymeworks Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zymeworks? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zymeworks and other key companies, straight to your email. Email Address About ZymeworksZymeworks (NASDAQ:ZYME) (NASDAQ: ZYME) is a biopharmaceutical company focused on discovering, developing and commercializing engineered antibody-based therapeutics for cancer and other serious diseases. The company’s technologies are designed to create bispecific and multispecific antibodies, as well as antibody-drug conjugates that can target tumor cells and deliver therapeutic payloads. Zymeworks’ leading product is zanidatamab, marketed in the United States as Ziihera. The bispecific antibody targets two separate sites on the HER2 protein and received U.S. Food and Drug Administration accelerated approval in 2024 for previously treated, unresectable, locally advanced or metastatic HER2-positive biliary tract cancer. The company continues to study zanidatamab in additional HER2-expressing cancers and treatment settings. The company’s research is supported by its proprietary Azymetric bispecific antibody and ZymeLink antibody-drug conjugate platforms. Founded in Vancouver, British Columbia, Zymeworks conducts research and development activities in North America and works with pharmaceutical partners to advance and commercialize its therapies in international markets. Its development portfolio has included additional antibody-based candidates for oncology applications.View Zymeworks ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
